Biodesix (BDSX) Research & Development (2019 - 2026)

Biodesix (BDSX) has 8 years of Research & Development data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Research & Development rose 18.3% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 44.57% YoY) and the FY2025 annual result came in at $7.6 million, down 20.89% from the prior year.
• Research & Development improved to $2.2 million in Q1 2026, from -$1.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $3.6 million in Q4 2022 to a low of -$1.6 million in Q4 2025.
• A 5-year average of $2.3 million and a median of $2.5 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development soared 487.39% — and 2025, when it slumped 144.8%.
• Tracing BDSX's Research & Development over 5 years: stood at $3.6 million in 2022, then sank by 125.36% to -$904000.0 in 2023, then soared by 487.39% to $3.5 million in 2024, then plunged by 144.8% to -$1.6 million in 2025, then soared by 240.92% to $2.2 million in 2026.
• The last three Research & Development figures came in at $2.2 million (Q1 2026), -$1.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.